||EPS - Basic
||Market Cap (m)
|Software & Computer Services
Instem Share Discussion Threads
Showing 851 to 873 of 875 messages
|I think run to 260p possible in short order.|
|Nothing to be concerned about on the update and the delayed orders to £1.2M should land 2017. Net cash increase of £1.9M
"Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism."
Increasing optimism - interesting.|
|Logos man sold out. Any price sub £2 is a bargain.|
|Look on the bright side, £700k less paid out but better if the acquisition had performed.|
|I'm still in the money on INS but have also decided to add a fair few.
I also see this as not a showstopper, just a trip on the way to the stage.|
|Looking at the price graph above who said info doesn't leak if that price move is from last Friday (I didn't check)?
Hold - these are delays and the foundations are still sound and the 2017 looking to have not been harmed.|
|Sbs went private.
Crx likely to be acquired.
|Pleasing to see this rise. Not many of us here so all the best whoever is on the same raft.I hold crx, held sbs, hold odx. A useful UK biotechnology grouping with ins.|
|Video interview with Phil Reason
Instem PLC (LON:INS) chief executive Phil Reason tells Proactive Investors that the company wants to “dominate” niche markets after it announced a solid first six months of trading in 2016.
“We think we can do as we do in many other areas of our business and be a market leader in a particular niche,” Reason says.
“We have some particular areas where we think we can dominate some of those niches.”
Reason adds that the biotech industry, the company’s main market, has been “buoyant” for the last couple of years and he expects it to remain that way for the foreseeable future.
“The contact research organisations that make up a lot of our client base today, their facilities are generally full as they conduct probably the largest numbers of studies they’ve ever enjoyed.”|
|Yup. One of my larger holdings.|
|Anyone else here. As bio turns round I expect this to move up a gear. Steady as she goes in the meantime.|
|Sensible looking acquisition.|
|Video interview with Nigel Goldsmith
Nigel Goldsmith, chief financial officer of Instem PLC (LON:INS) tells Proactive the firm had an “exceptionally good year in 2015”, which has given it a “very strong platform” for this year.
The company, which develops software used in clinical trials, recorded significant year-on-year growth in 2015 as its main markets continue to expand. Revenues increased by 22% in the 12 months to December 31 to £16.3mln, £10mln of which were recurring.
Instem also increased its cash reserves, and Goldsmith says this, combined with a £5mln fundraise, will allow the company to look at “new acquisitions” in a “fragmented sector” with “lots of opportunities”.|
|p1nkfish - is there any link to Instem wrt your posted Telegraph article?|
|And this has what to do with Instem? They provide software for managing data for preclinical and early stage clinical drugs. Nothing to do with the drugs themselves.|
|Trading statement due any day?
Past few years has been around now.|
|Lovely move today.|
|I bought quite a few in the 130-140p area. They're market leaders in their niche but are subject to pharma R&D cutbacks every so often so have the odd setback. Usually a good opportunity to buy.|
|Rise in short time from 135p to well over 200p and no postings. A huge contract win. Very strange BB.
Just bought in, a small purchase, after over a year watching this one.|
|Video interview with CEO Phil Reason
Phil Reason, the chief executive of Instem (LON:INS), says he is very excited by the opportunity offered by Centrus-submit solution, which enables non-clinical data to be sent to the FDA by electronically rather than on paper.
‘That’s got a huge potential to reduce the amount of time it takes a regulatory reviewer to complete their review of a regulatory submission and accelerate the pace at which a new drug can come to market,’ Reason explains.
Instem’s CEO also discusses the newsflow that he hopes will drive the share price higher.|
|Zak Mir takes a charting look at the trending stocks of the moment, AFCR, JQW, REM, INS
4 December, 2014
|Results due Wednesday.|